{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:10:16Z","timestamp":1785168616056,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["KLI 861-B"],"award-info":[{"award-number":["KLI 861-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical-scientific fund of the Mayor of the federal capital Vienna","award":["MA 40-GMWF-COVID027"],"award-info":[{"award-number":["MA 40-GMWF-COVID027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SARS-CoV-2 gains cell entry via angiotensin-converting enzyme (ACE) 2, a membrane-bound enzyme of the \u201calternative\u201d (alt) renin-angiotensin system (RAS). ACE2 counteracts angiotensin II by converting it to potentially protective angiotensin 1\u20137. Using mass spectrometry, we assessed key metabolites of the classical RAS (angiotensins I\u2013II) and alt-RAS (angiotensins 1\u20137 and 1\u20135) pathways as well as ACE and ACE2 concentrations in 159 patients hospitalized with COVID-19, stratified by disease severity (severe, n\u2009=\u200976; non-severe: n\u2009=\u200983). Plasma renin activity (PRA-S) was calculated as the sum of RAS metabolites. We estimated ACE activity using the angiotensin II:I ratio (ACE-S) and estimated systemic alt-RAS activation using the ratio of alt-RAS axis metabolites to PRA-S (ALT-S). We applied mixed linear models to assess how PRA-S and ACE\/ACE2 concentrations affected ALT-S, ACE-S, and angiotensins II and 1-7. Median angiotensin I and II levels were higher with severe versus non-severe COVID-19 (angiotensin I: 86 versus 30\u00a0pmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01; angiotensin II: 114 versus 58\u00a0pmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), demonstrating activation of classical RAS. The difference disappeared with analysis limited to patients not taking a RAS inhibitor (angiotensin I: 40 versus 31\u00a0pmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.251; angiotensin II: 76 versus 99\u00a0pmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.833). ALT-S in severe COVID-19 increased with time (days 1\u20136: 0.12; days 11\u201316: 0.22) and correlated with ACE2 concentration (r\u2009=\u20090.831). ACE-S was lower in severe versus non-severe COVID-19 (1.6 versus 2.6; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), but ACE concentrations were similar between groups and correlated\u00a0weakly with ACE-S (r\u2009=\u20090.232). ACE2 and ACE-S trajectories in severe COVID-19, however, did not differ between survivors and non-survivors. Overall RAS alteration in severe COVID-19 resembled severity of disease-matched patients with influenza. In mixed linear models, renin activity most strongly predicted angiotensin II and 1-7 levels. ACE2 also predicted angiotensin 1-7 levels and ALT-S. No single factor or the combined model, however, could fully explain ACE-S. ACE2 and ACE-S trajectories in severe COVID-19 did not differ between survivors and non-survivors. In conclusion,\u00a0angiotensin II was elevated in severe COVID-19 but was\u00a0markedly influenced by RAS inhibitors and driven by overall RAS activation. ACE-S was significantly lower with severe COVID-19 and did not correlate with ACE concentrations. A shift to the alt-RAS axis because of increased ACE2 could partially explain the relative reduction in angiotensin II levels.<\/jats:p>","DOI":"10.1038\/s41598-022-24628-1","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T09:11:02Z","timestamp":1669194662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The systemic renin-angiotensin system in COVID-19"],"prefix":"10.1038","volume":"12","author":[{"given":"Roman","family":"Reindl-Schwaighofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"H\u00f6dlmoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Krenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farsad","family":"Eskandary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Krenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sch\u00f6rgenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Rumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Karolyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna T.","family":"Traugott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Abrahamowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Tinhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Mayfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rathkolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mu\u00dfnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Schm\u00f6lz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Heinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Puchhammer-St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Gorkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith H.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zoufaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"17","key":"24628_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med. 382(17), 1653\u20131659 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"24628_CR2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/HYPERTENSIONAHA.118.10918","volume":"72","author":"M Bader","year":"2018","unstructured":"Bader, M. et al. The meaning of mas. Hypertension 72(5), 1072\u20131075 (2018).","journal-title":"Hypertension"},{"issue":"2","key":"24628_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1253\/circj.CJ-12-1544","volume":"77","author":"K Kuba","year":"2013","unstructured":"Kuba, K., Imai, Y. & Penninger, J. M. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J 77(2), 301\u2013308 (2013).","journal-title":"Circ J"},{"key":"24628_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271 (2020).","journal-title":"Cell"},{"key":"24628_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel, V. B. et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: A positive feedback mechanism in the RAS. J. Mol. Cell Cardiol. 66, 167\u2013176 (2014).","journal-title":"J. Mol. Cell Cardiol."},{"issue":"7798","key":"24628_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270\u2013273 (2020).","journal-title":"Nature"},{"issue":"8","key":"24628_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11(8), 875\u2013879 (2005).","journal-title":"Nat Med"},{"issue":"1","key":"24628_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","volume":"9","author":"MY Li","year":"2020","unstructured":"Li, M. Y. et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 9(1), 45 (2020).","journal-title":"Infect. Dis. Poverty"},{"key":"24628_CR9","unstructured":"Rysz, S., Al-Saadi, J., Sj\u00f6str\u00f6m, A. et al. COVID-19 pathophysiology may be driven by a loss of inhibition of the Renin-Angiotensin-Aldosterone System https:\/\/www.researchsquare.com\/article\/rs-32494\/v2"},{"issue":"3","key":"24628_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 63(3), 364\u2013374 (2020).","journal-title":"Sci. China Life Sci."},{"key":"24628_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1164\/rccm.202101-0142LE","volume":"203","author":"R Reindl-Schwaighofer","year":"2021","unstructured":"Reindl-Schwaighofer, R. et al. Angiotensin-converting enzyme 2 (ACE2) elevation in severe COVID-19. Am. J. Respir. Crit. Care Med. 203, 1191 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"24628_CR12","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20(8):e192-e197 (2020)"},{"issue":"1","key":"24628_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13054-020-02902-w","volume":"24","author":"G Deng","year":"2020","unstructured":"Deng, G. et al. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit. Care 24(1), 179 (2020).","journal-title":"Crit. Care"},{"issue":"6","key":"24628_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-8587(21)00089-9","volume":"9","author":"M Gao","year":"2021","unstructured":"Gao, M. et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: A prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 9(6), 350\u2013359 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"24628_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/clinchem\/hvaa001","volume":"66","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism. Clin. Chem. 66(3), 483\u2013492 (2020).","journal-title":"Clin. Chem."},{"issue":"6","key":"24628_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1161\/HYPERTENSIONAHA.119.13982","volume":"75","author":"SA Urwyler","year":"2020","unstructured":"Urwyler, S. A. et al. IL (Interleukin)-1 receptor antagonist increases ang (angiotensin [1-7]) and decreases blood pressure in obese individuals. Hypertension 75(6), 1455\u20131463 (2020).","journal-title":"Hypertension"},{"issue":"7","key":"24628_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","volume":"69","author":"R Basu","year":"2017","unstructured":"Basu, R. et al. Roles of angiotensin peptides and recombinant human ACE2 in heart failure. J. Am. Coll. Cardiol. 69(7), 805\u2013819 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"24628_CR18","doi-asserted-by":"publisher","first-page":"147032031770523","DOI":"10.1177\/1470320317705232","volume":"18","author":"M Antlanger","year":"2017","unstructured":"Antlanger, M. et al. Molecular remodeling of the renin-angiotensin system after kidney transplantation. J. Renin. Angiotensin Aldosterone Syst. 18(2), 1470320317705232 (2017).","journal-title":"J. Renin. Angiotensin Aldosterone Syst."},{"issue":"2","key":"24628_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","volume":"76","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin II ratio in patients with primary aldosteronism. Hypertension 76(2), 488\u2013496 (2020).","journal-title":"Hypertension"},{"key":"24628_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30418-5","author":"A Zoufaly","year":"2020","unstructured":"Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30418-5 (2020).","journal-title":"Lancet Respir. Med."},{"issue":"134","key":"24628_CR21","doi-asserted-by":"publisher","first-page":"20170213","DOI":"10.1098\/rsif.2017.0213","volume":"14","author":"S Nakagawa","year":"2017","unstructured":"Nakagawa, S., Johnson, P. C. D. & Schielzeth, H. The coefficient of determination R(2) and intra-class correlation coefficient from generalized linear mixed-effects models revisited and expanded. J. R. Soc. Interface 14(134), 20170213 (2017).","journal-title":"J. R. Soc. Interface"},{"issue":"10256","key":"24628_CR22","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(20)31964-4","volume":"396","author":"S Narula","year":"2020","unstructured":"Narula, S. et al. Plasma ACE2 and risk of death or cardiometabolic diseases: A case-cohort analysis. Lancet 396(10256), 968\u2013976 (2020).","journal-title":"Lancet"},{"issue":"2","key":"24628_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","volume":"47","author":"PJ Gleeson","year":"2019","unstructured":"Gleeson, P. J. et al. Renin as a marker of tissue-perfusion and prognosis in critically Ill patients. Crit. Care Med. 47(2), 152\u2013158 (2019).","journal-title":"Crit. Care Med."},{"key":"24628_CR24","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1038\/ncomms4595","volume":"5","author":"F Huang","year":"2014","unstructured":"Huang, F. et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat. Commun. 5, 3595 (2014).","journal-title":"Nat. Commun."},{"issue":"6","key":"24628_CR25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1681\/ASN.2009030307","volume":"21","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. Stimulation of renin secretion by angiotensin II blockade is Gsalpha-dependent. J. Am. Soc. Nephrol. 21(6), 986\u2013992 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"24628_CR26","doi-asserted-by":"publisher","first-page":"L213","DOI":"10.1152\/ajplung.00129.2021","volume":"321","author":"DC Files","year":"2021","unstructured":"Files, D. C. et al. A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure. Am. J. Physiol. Lung Cell Mol. Physiol. 321(1), L213\u2013L218 (2021).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"6","key":"24628_CR27","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1097\/CCM.0000000000004967","volume":"49","author":"S Ozkan","year":"2021","unstructured":"Ozkan, S. et al. Efficacy of serum angiotensin II levels in Prognosis of patients with coronavirus disease 2019. Crit. Care Med. 49(6), e613\u2013e623 (2021).","journal-title":"Crit. Care Med."},{"key":"24628_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.19.210955","author":"OO Onabajo","year":"2020","unstructured":"Onabajo, O. O. et al. Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. bioRxiv https:\/\/doi.org\/10.1101\/2020.07.19.210955 (2020).","journal-title":"bioRxiv"},{"key":"24628_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.856891","volume":"9","author":"R Reindl-Schwaighofer","year":"2022","unstructured":"Reindl-Schwaighofer, R. et al. Corticosteroid treatment prevents lipopolysaccharide-induced increase of ACE2 and reduces fibrin degradation products in bronchoalveolar lavage fluid. Front. Med. (Lausanne) 9, 856891 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"9","key":"24628_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1164\/rccm.202012-4461OC","volume":"204","author":"L Gerard","year":"2021","unstructured":"Gerard, L. et al. Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19-related acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 204(9), 1024\u20131034 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"24628_CR31","doi-asserted-by":"crossref","unstructured":"Wang, K., Gheblawi, M., Nikhanj, A., et al. Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and renin-angiotensin peptides in SARS-CoV-2 mediated mortality and end-organ injuries. Hypertension 2021:HYPERTENSIONAHA12118295","DOI":"10.1161\/HYPERTENSIONAHA.121.18295"},{"key":"24628_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijid.2021.11.028","volume":"115","author":"M Fagyas","year":"2021","unstructured":"Fagyas, M. et al. Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients. Int. J. Infect. Dis. 115, 8\u201316 (2021).","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"24628_CR33","doi-asserted-by":"publisher","first-page":"2003730","DOI":"10.1183\/13993003.03730-2020","volume":"57","author":"SK Patel","year":"2021","unstructured":"Patel, S. K. et al. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. Eur. Respir. J. 57(5), 2003730 https:\/\/doi.org\/10.1183\/13993003.03730-2020 (2021).","journal-title":"Eur. Respir. J."},{"issue":"1","key":"24628_CR34","doi-asserted-by":"publisher","first-page":"00848","DOI":"10.1183\/23120541.00848-2020","volume":"7","author":"D van Lier","year":"2021","unstructured":"van Lier, D. et al. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 7(1), 00848\u20132020 https:\/\/doi.org\/10.1183\/23120541.00848-2020 (2021).","journal-title":"ERJ Open Res."},{"issue":"6","key":"24628_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252799","volume":"16","author":"TW Kragstrup","year":"2021","unstructured":"Kragstrup, T. W. et al. Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients. PLoS ONE 16(6), e0252799 (2021).","journal-title":"PLoS ONE"},{"key":"24628_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.653045","volume":"12","author":"G Kaur","year":"2021","unstructured":"Kaur, G. et al. Persistently increased systemic ACE2 activity is associated with an increased inflammatory response in smokers with COVID-19. Front. Physiol. 12, 653045 (2021).","journal-title":"Front. Physiol."},{"key":"24628_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijid.2020.11.184","volume":"103","author":"B Nagy Jr","year":"2021","unstructured":"Nagy, B. Jr. et al. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int. J. Infect. Dis. 103, 412\u2013414 (2021).","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"24628_CR38","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1161\/HYPERTENSIONAHA.120.15841","volume":"76","author":"U Kintscher","year":"2020","unstructured":"Kintscher, U. et al. Plasma angiotensin peptide profiling and ACE (angiotensin-converting enzyme)-2 activity in COVID-19 patients treated with pharmacological blockers of the renin-angiotensin system. Hypertension 76(5), e34\u2013e36 (2020).","journal-title":"Hypertension"},{"issue":"3","key":"24628_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/ajh\/hpaa169","volume":"34","author":"M Rieder","year":"2021","unstructured":"Rieder, M. et al. Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. Am. J. Hypertens 34(3), 278\u2013281 (2021).","journal-title":"Am. J. Hypertens"},{"issue":"3","key":"24628_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/ajh\/hpaa178","volume":"34","author":"M Rojas","year":"2021","unstructured":"Rojas, M. et al. How important is the assessment of soluble ACE-2 in COVID-19?. Am. J. Hypertens 34(3), 296\u2013297 (2021).","journal-title":"Am. J. Hypertens"},{"issue":"1","key":"24628_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","volume":"75","author":"P Serfozo","year":"2020","unstructured":"Serfozo, P. et al. Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation Is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension 75(1), 173\u2013182 (2020).","journal-title":"Hypertension"},{"issue":"10","key":"24628_CR42","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1164\/rccm.201912-2504LE","volume":"202","author":"K Krenn","year":"2020","unstructured":"Krenn, K. et al. Equilibrium angiotensin metabolite profiling in patients with acute respiratory distress syndrome indicates angiotensin-converting enzyme inhibition. Am. J. Respir. Crit. Care Med. 202(10), 1468\u20131471 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"24628_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","volume":"24","author":"R Bellomo","year":"2020","unstructured":"Bellomo, R. et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit. Care 24(1), 43 (2020).","journal-title":"Crit. Care"},{"key":"24628_CR44","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1097\/CCM.0000000000005495","volume":"50","author":"X Mao","year":"2022","unstructured":"Mao, X. et al. Tidal volume-dependent activation of the renin-angiotensin system in experimental ventilator-induced lung injury. Crit. Care Med. 50, e696 (2022).","journal-title":"Crit. Care Med."},{"issue":"3","key":"24628_CR45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1373\/clinchem.2017.278705","volume":"64","author":"N Pavo","year":"2018","unstructured":"Pavo, N. et al. Low- and high-renin heart failure phenotypes with clinical implications. Clin. Chem. 64(3), 597\u2013608 (2018).","journal-title":"Clin. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24628-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T09:18:55Z","timestamp":1669195135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24628-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24628"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24628-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marko Poglitsch and Oliver Domenig are employed by Attoquant Diagnostics, Vienna\/Austria, a company that received payments for RAS-Fingerprint and ACE2 measurements. None of the other co-authors declared a competing interest related to the present manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20117"}}